A Cautionary Tale: Declining Renal Function Following Acute Rejection Post Conversion From Calcineurin Inhibitor to Belatacept in HLA-sensitized Individuals in the First Posttransplant Year.
作者信息
Banham Gemma D
机构信息
The Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
出版信息
Transplantation. 2020 Jul;104(7):1322-1323. doi: 10.1097/TP.0000000000002979.
PMID:32569003
Abstract
摘要
相似文献
1
A Cautionary Tale: Declining Renal Function Following Acute Rejection Post Conversion From Calcineurin Inhibitor to Belatacept in HLA-sensitized Individuals in the First Posttransplant Year.
Transplantation. 2020 Jul;104(7):1322-1323. doi: 10.1097/TP.0000000000002979.
2
Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Transplantation. 2020 Jul;104(7):1500-1507. doi: 10.1097/TP.0000000000002976.
3
Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
Transplantation. 2019 Oct;103(10):2150-2156. doi: 10.1097/TP.0000000000002592.
4
Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Am J Transplant. 2019 Aug;19(8):2342-2349. doi: 10.1111/ajt.15319. Epub 2019 Mar 12.
5
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.
6
Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
BMC Nephrol. 2020 Aug 20;21(1):354. doi: 10.1186/s12882-020-01992-6.
7
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628.
8
Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
Am J Transplant. 2020 Apr;20(4):1039-1055. doi: 10.1111/ajt.15688. Epub 2020 Feb 6.
9
Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2.
Adv Chronic Kidney Dis. 2016 Sep;23(5):306-311. doi: 10.1053/j.ackd.2016.09.004.
10
Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Am J Transplant. 2016 Jul;16(7):2181-6. doi: 10.1111/ajt.13698. Epub 2016 Mar 2.
引用本文的文献
1
Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.
PLoS One. 2020 Oct 15;15(10):e0240335. doi: 10.1371/journal.pone.0240335. eCollection 2020.
Zotero 插件